Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Jon Cheng, M.D., is a Vice President and Oncology Therapeutic Area Head at Merck Research Laboratories (MRL). He leads the Late Stage Clinical Development at Merck Oncology, and in this role oversees the clinical development of all late stage clinical assets including pembrolizumab and its combinations in multiple solid organ tumors including lung, head/neck, gastrointestinal, breast, gyn, and hematologic malignancies.
Dr. Cheng joined Merck in 2008 where he had previous responsibilities developing novel combinations within the Merck pipeline, incorporating biomarkers and companion diagnostic development into clinical trials, and directed a number of pembrolizumab registrational activities including supervising the approval of pembrolizumab in head/neck and gastric cancer.